| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1011800527 |
| P356 | DOI | 10.1007/S11914-010-0027-Y |
| P953 | full work available at URL | http://www.current-reports.com/1544-1873/8/178 |
| https://europepmc.org/articles/PMC2947013 | ||
| https://link.springer.com/content/pdf/10.1007/s11914-010-0027-y.pdf | ||
| https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20809203/?tool=EBI | ||
| https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20809203/pdf/?tool=EBI | ||
| https://europepmc.org/articles/PMC2947013?pdf=render | ||
| P932 | PMC publication ID | 2947013 |
| P698 | PubMed publication ID | 20809203 |
| P5875 | ResearchGate publication ID | 46108944 |
| P2093 | author name string | Beata Lecka-Czernik | |
| P2860 | cites work | Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 |
| Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis | Q24655666 | ||
| Fat and beyond: the diverse biology of PPARgamma | Q29615416 | ||
| Genetic regulation of osteoclast development and function | Q29617421 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| The risk of fractures associated with thiazolidinediones: a self-controlled case-series study | Q33507247 | ||
| Oral antihyperglycemic therapy for type 2 diabetes mellitus. | Q33713451 | ||
| Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus | Q33736122 | ||
| Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1 | Q33821740 | ||
| Thiazolidinediones | Q34346862 | ||
| Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways | Q34371949 | ||
| PPAR-gamma regulates osteoclastogenesis in mice | Q34585778 | ||
| Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). | Q34587610 | ||
| Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 | ||
| Thiazolidinedione use and bone loss in older diabetic adults | Q35023205 | ||
| Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. | Q35745608 | ||
| Bone is a target for the antidiabetic compound rosiglitazone. | Q35758012 | ||
| Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly | Q36147952 | ||
| Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone | Q36157326 | ||
| PPARgamma2 Regulates a Molecular Signature of Marrow Mesenchymal Stem Cells | Q36446012 | ||
| Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes | Q36536290 | ||
| Mechanisms of disease: is osteoporosis the obesity of bone? | Q36577405 | ||
| Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies | Q36844378 | ||
| Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture | Q36851830 | ||
| Fracture risk in type 2 diabetes: update of a population-based study | Q36952446 | ||
| Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). | Q37235840 | ||
| Skeletal consequences of deletion of steroid receptor coactivator-2/transcription intermediary factor-2. | Q37253958 | ||
| Pentosidine and increased fracture risk in older adults with type 2 diabetes | Q37257534 | ||
| A cohort study of thiazolidinediones and fractures in older adults with diabetes | Q37315675 | ||
| PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells | Q37349947 | ||
| Distal upper and lower limb fractures associated with thiazolidinedione use. | Q37577884 | ||
| Bone as a target of type 2 diabetes treatment. | Q37602619 | ||
| Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation | Q37631296 | ||
| Gastrointestinal peptides and bone health | Q37631367 | ||
| Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells | Q37736265 | ||
| PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism | Q37738780 | ||
| Use of thiazolidinediones and fracture risk | Q38456774 | ||
| The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial | Q40247162 | ||
| Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation | Q40731268 | ||
| Avandia outcome may signal change in epidemiologists' sway | Q43043687 | ||
| The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial | Q43114233 | ||
| Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus | Q43174291 | ||
| Rosiglitazone therapy is associated with major clinical improvements in a patient with fibrodysplasia ossificans progressiva | Q43237737 | ||
| Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes | Q43252247 | ||
| Thiazolidinediones and fractures in men and women | Q43295115 | ||
| Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). | Q45154098 | ||
| Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes | Q46208153 | ||
| Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse | Q46214478 | ||
| Older women with diabetes have a higher risk of falls: a prospective study | Q46226154 | ||
| Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial | Q46745142 | ||
| Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes | Q46832348 | ||
| Collagen glycation and its role in fracture properties of bone. | Q51306961 | ||
| Bone loss and bone turnover in diabetes | Q72332597 | ||
| Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications | Q82803173 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoporosis | Q165328 |
| heterocyclic compound | Q193430 | ||
| thiazoles | Q2420555 | ||
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 178-184 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Current osteoporosis reports | Q26841869 |
| P1476 | title | Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis | |
| P478 | volume | 8 |
| Q48275468 | ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease. |
| Q38150258 | Adipocytes and the regulation of bone remodeling: a balancing act. |
| Q37426679 | All-trans retinoic acid shifts rosiglitazone-induced adipogenic differentiation to osteogenic differentiation in mouse embryonic fibroblasts |
| Q44899614 | Androgens and estrogens prevent rosiglitazone-induced adipogenesis in human mesenchymal stem cells |
| Q47559348 | Biological effects of melatonin on osteoblast/osteoclast cocultures, bone, and quality of life: Implications of a role for MT2 melatonin receptors, MEK1/2, and MEK5 in melatonin-mediated osteoblastogenesis. |
| Q27010173 | Bone as an endocrine organ |
| Q39022309 | Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. |
| Q34197048 | Bone marrow fat has brown adipose tissue characteristics, which are attenuated with aging and diabetes |
| Q37134718 | Causes, consequences, and treatment of osteoporosis in men. |
| Q64259048 | Cooperative impact of thiazolidinedione and fatty acid synthase on human osteogenesis |
| Q39328894 | D-chiro-inositol negatively regulates the formation of multinucleated osteoclasts by down-regulating NFATc1. |
| Q37965266 | Diabetes and fracture healing: the skeletal effects of diabetic drugs |
| Q38084724 | Diabetes mellitus and inflammatory pulpal and periapical disease: a review. |
| Q38087556 | Diabetes mellitus and osteoporosis |
| Q33843692 | Diabetes, bone and glucose-lowering agents: basic biology |
| Q51298932 | Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes. |
| Q51761248 | Evidence of Drug-Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update. |
| Q37511845 | Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences |
| Q35911081 | Fracture incidence and risk of osteoporosis in female type 2 diabetic patients in Korea |
| Q36649815 | Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl. |
| Q35759258 | Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients |
| Q36297873 | Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. |
| Q36900471 | Hyperglycemia induces endoplasmic reticulum stress-dependent CHOP expression in osteoblasts |
| Q35574560 | Management of diabetes across the course of disease: minimizing obesity-associated complications |
| Q30238940 | Medical Management of Diabesity: Do We Have Realistic Targets? |
| Q37643521 | Melatonin-micronutrients Osteopenia Treatment Study (MOTS): a translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal os |
| Q55240881 | Metformin and Autoimmunity: A "New Deal" of an Old Drug. |
| Q35054970 | Minireview: nuclear receptor regulation of osteoclast and bone remodeling |
| Q38932554 | Non-alcoholic fatty liver disease in 2016. |
| Q42913256 | Non-alcoholic fatty liver disease: a practical approach to treatment |
| Q33351754 | Osteoporosis piece of multi-morbidity puzzle in geriatric care |
| Q27334866 | Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass |
| Q35998796 | Pathophysiological role of enhanced bone marrow adipogenesis in diabetic complications. |
| Q37964751 | Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review |
| Q36558095 | Reciprocal Control of Osteogenic and Adipogenic Differentiation by ERK/MAP Kinase Phosphorylation of Runx2 and PPARγ Transcription Factors |
| Q28270738 | Recognizing and treating secondary osteoporosis |
| Q35135556 | Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. |
| Q38662765 | Review article: new treatments in non-alcoholic fatty liver disease. |
| Q38442816 | Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies |
| Q36299797 | Rheumatic manifestations in diabetic patients |
| Q88779484 | Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation |
| Q36779975 | Rosiglitazone inhibits bone regeneration and causes significant accumulation of fat at sites of new bone formation |
| Q51285465 | ST1926 Attenuates Steroid-Induced Osteoporosis in Rats by Inhibiting Inflammation Response. |
| Q36716222 | Safety of Anti-Diabetic Therapies on Bone |
| Q43814969 | Sirtuin-3 Promotes Adipogenesis, Osteoclastogenesis, and Bone Loss in Aging Male Mice |
| Q28078585 | The Bone Marrow-Derived Stromal Cells: Commitment and Regulation of Adipogenesis |
| Q37182800 | The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing. |
| Q52836232 | The effects of diabetes medications on post-operative long bone fracture healing. |
| Q37461510 | The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption |
| Q39096039 | The multi-faceted role of retinoid X receptor in bone remodeling. |
| Q38049949 | There are many potential medical therapies for atraumatic osteonecrosis |
| Q35496098 | Thiazolidinediones on PPARγ: The Roles in Bone Remodeling |
| Q37953155 | Transitioning from inpatient to outpatient therapy in patients with in-hospital hyperglycemia |
| Q37105051 | VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease. |
| Q58091922 | VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity |
| Q38979293 | Vitamin D Level Between Calcium-Phosphorus Homeostasis and Immune System: New Perspective in Osteoporosis. |
Search more.